Objective: The objectives of this analysis were to: Identify a population of schizophrenia patients treated within a commercial managed care environment. Describe and compare the prevalence of conditions associated with metabolic syndrome in patients treated with antipsychotics agents. Methods: Using integrated medical and pharmacy claims data (obtained from the IMS/Pharmetrics Patient-centric Database), patients were included in this analysis based on the presence of a diagnosis of schizophrenia (ICD-9 code 295.*) in 2005. Clinical and economic information related to the treatment of schizophrenia were captured using Episode Treatment Group™ (ETG™) episode-building software. Results: In 2005, 8594 schizophrenia patients were identified; within this population, the average age was 45.7 years and 46% was male. Co-morbid conditions included bipolar disorders (in 23.7% of patients), anxiety disorder (12.7%), substance dependence (11.7%), and depression (7.9%). Overall (among the entire identified patient population), 75.6% of patients used antipsychotics; 57.4% used only atypical agents, 9.1% used only conventional agents and 9.1% used both. Overall, 48.6% of patients had at least one of the following conditions, considered markers for metabolic syndrome: diabetes, hyperlipidemia, hypertension, or obesity. Among patients treated with antipsychotics, prevalence of these conditions was lowest in those treated only with atypical agents (46.5% with at least one condition), higher in patients treated only with conventional agents (55.5% with at least one condition), and highest in patients with use of both classes of antipsychotic agents. Conclusion: The schizophrenia population observed in this analysis reflected a lower prevalence of presumed metabolic syndrome in groups treated with atypical antipsychotic agents. This observation contradicts other research. This disparity may be attributable to differences in patient demographics or other confounding factors, but nonetheless warrants further study.